| Dr John Mcdowell Kalbfleisch, MD | |
|
6151 S Yale Ave, Suite 400, Tulsa, OK 74136-1907 | |
| (918) 494-8500 | |
| (918) 307-5578 |
| Full Name | Dr John Mcdowell Kalbfleisch |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 6151 S Yale Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326093501 | NPI | - | NPPES |
| P00409625 | Other | OK | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 7170 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Mcdowell Kalbfleisch, MD 6151 S Yale Ave, Suite 400, Tulsa, OK 74136-1907 Ph: (918) 494-8500 | Dr John Mcdowell Kalbfleisch, MD 6151 S Yale Ave, Suite 400, Tulsa, OK 74136-1907 Ph: (918) 494-8500 |
News Archive
A U.S.-funded initiative to improve quality of care and referrals during pregnancy and childbirth in Indonesia resulted in significant reductions in maternal and newborn mortality at participating hospitals, according to a new study led by scientists at the Johns Hopkins Bloomberg School of Public Health.
Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.
A landmark study by Florida State University biologists, in collaboration with scientists in Britain, is the first to identify a life-or-death "cell competition" process in mammalian tissue that suppresses cancer by causing cancerous cells to kill themselves.
QLT Inc. today announced that final results from the Novartis-sponsored Phase IIIb DENALI study were presented on June 8, 2010 during the World Ophthalmology Congress in Berlin. DENALI was a 24-month randomized, double-masked, multicenter trial in patients with subfoveal choroidal neovascularization secondary to wet age-related macular degeneration (all lesion types).
› Verified 8 days ago
Sarah Anne Shaw-dressler, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave Ste 100a, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Julia Margaret Kwon, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1705 E 19th St Ste 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Peter Madden, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 E 41st St, Tulsa, OK 74135 Phone: 918-619-4400 | |
Thao Tran, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 E. 41st Street, Tulsa, OK 74135 Phone: 918-619-4400 | |
Robert Peter Aran, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6160 S Yale Ave Ste 100, Tulsa, OK 74136 Phone: 918-497-3300 Fax: 918-497-3365 | |
Robert Dean Okada, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave, Ste 304, Tulsa, OK 74136 Phone: 918-494-5300 Fax: 918-494-5455 | |
Dr. Charles Wade Taylor, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12697 E 51st St, Tulsa, OK 74146 Phone: 918-505-3200 Fax: 918-505-3253 |